Blincyto 38.5 mcg (Blinatumomab POWDER FOR SOLUTION) 38.5 MCG

Blincyto 38.5 mcg is a powder for solution used in intravenous therapy. This medication is designed to target specific cells in the body, often utilized in specialized treatment plans. Learn more about Blincyto's uses and effects.

Strength

38.5 MCG

Pack Size

265ML TO 275ML (STARTING VOL)

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Blincyto 38.5 mcg is primarily used in intravenous therapy to target certain cells in the body. It is often part of a broader treatment strategy for conditions that involve abnormal cell activity. Patients and healthcare providers may explore Blincyto's uses to understand its role in managing specific health concerns.

Side Effects

Blincyto 38.5 mcg may cause various effects, including common reactions like fatigue and fever. Some individuals might experience more severe responses, highlighting the importance of monitoring during treatment. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Handling Blincyto 38.5 mcg requires careful attention to dosage and administration guidelines. It is crucial to follow the prescribed protocol and monitor for any adverse reactions. Patients should discuss their medical history with their healthcare provider before starting treatment.

Avoid Interactions

Blincyto 38.5 mcg may interact with other medications, particularly those that affect the immune system. It is important to inform your healthcare provider about all current medications to avoid potential interactions. Always follow medical advice regarding drug combinations.

Frequently Asked Questions

Blincyto 38.5 mcg is used in intravenous therapy to target specific cells in the body, often as part of a treatment plan for conditions involving abnormal cell activity.

Blincyto 38.5 mcg is administered intravenously, typically in a clinical setting under the supervision of a healthcare provider.

Common effects of Blincyto 38.5 mcg may include fatigue, fever, and other reactions. Severe responses are possible, emphasizing the need for medical monitoring.

Precautions include following the prescribed dosage and administration guidelines, monitoring for adverse reactions, and discussing medical history with a healthcare provider.

Blincyto 38.5 mcg may interact with other medications, especially those affecting the immune system. Always inform your healthcare provider about all current medications.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.